NEWS DETAIL

FDAは、標的療法が適用できない急性骨髄性白血病患者に対し、デシタビン/シダザロリドとベネトクラクスの併用療法を承認した – Targeted Oncology

米国食品医薬品局(FDA)は、標的がん治療の適応とならない急性骨髄性白血病患者に対し、デシタビン/シダザロリドとベネトクラクスの併用療法を承認した。

医療情報

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Produits lies a cet article

Ces produits ont ete automatiquement associes au titre, au resume et au contenu de l article.

Questions frequentes

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Quizartinib – Acheter en ligne Lucius Anagrelide – Acheter en ligne Lucius Tazemetostat – Acheter en ligne Lucius Acalabrutinib – Acheter en ligne.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat